loading
Minerva Neurosciences Inc stock is traded at $2.17, with a volume of 12,789. It is up +2.12% in the last 24 hours and down -14.93% over the past month. Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
See More
Previous Close:
$2.12
Open:
$2.145
24h Volume:
12,789
Relative Volume:
0.78
Market Cap:
$14.95M
Revenue:
-
Net Income/Loss:
$-33.65M
P/E Ratio:
-0.4357
EPS:
-4.98
Net Cash Flow:
$-20.83M
1W Performance:
-6.68%
1M Performance:
-14.93%
6M Performance:
-11.99%
1Y Performance:
-56.70%
1-Day Range:
Value
$2.14
$2.2299
1-Week Range:
Value
$2.0703
$2.345
52-Week Range:
Value
$2.0703
$13.49

Minerva Neurosciences Inc Stock (NERV) Company Profile

Name
Name
Minerva Neurosciences Inc
Name
Phone
617-600-7373
Name
Address
1601 TRAPELO ROAD, WALTHAM, MA
Name
Employee
9
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
NERV's Discussions on Twitter

Compare NERV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
NERV 2.165 14.95M 0 -33.65M -20.83M -4.98
VRTX 449.18 115.74B 10.63B -479.80M -1.35B 13.33
REGN 746.98 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 592.97 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.49 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.97 24.49B 3.30B -501.07M 1.03B 11.54

Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-08-20 Reiterated H.C. Wainwright Buy
May-14-20 Initiated BTIG Research Buy
Oct-02-19 Reiterated Chardan Capital Markets Buy
Sep-25-19 Initiated Chardan Capital Markets Buy
Sep-18-19 Initiated William Blair Outperform
May-31-19 Initiated H.C. Wainwright Buy
Sep-01-17 Initiated Citigroup Buy
Mar-06-17 Resumed Jefferies Buy
May-12-16 Resumed Jefferies Buy
View All

Minerva Neurosciences Inc Stock (NERV) Latest News

pulisher
01:12 AM

Reviewing Vistagen Therapeutics (NASDAQ:VTGN) and Minerva Neurosciences (NASDAQ:NERV) - Defense World

01:12 AM
pulisher
Nov 15, 2024

500: Something went wrong - Investing.com

Nov 15, 2024
pulisher
Nov 15, 2024

Minerva Neurosciences stock hits 52-week low at $2.25 By Investing.com - Investing.com Canada

Nov 15, 2024
pulisher
Nov 10, 2024

Minerva Neurosciences’ (NERV) “Neutral” Rating Reiterated at HC Wainwright - Defense World

Nov 10, 2024
pulisher
Nov 05, 2024

Minerva Neurosciences Reports Positive Earnings Amid FDA Challenges - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Minerva Neurosciences: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 05, 2024
pulisher
Nov 05, 2024

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Minerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 05, 2024
pulisher
Oct 29, 2024

Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail

Oct 29, 2024
pulisher
Oct 13, 2024

Cognitive Impairment Disorders Treatment A Game Changer for Global Finance Forecast-Eli Lilly and Company, AstraZeneca, – IndiaPolitics.com - IndiaPolitics.com

Oct 13, 2024
pulisher
Oct 11, 2024

Japan Receptor Tyrosine Protein Kinase ERBB 4 Industry Size, Share, Price, Trends, Forecast (2024-2034) - IndiaPolitics.com

Oct 11, 2024
pulisher
Oct 09, 2024

Minerva Neurosciences (NASDAQ:NERV) Share Price Passes Below 200-Day Moving Average – What’s Next? - Defense World

Oct 09, 2024
pulisher
Sep 30, 2024

Schizophrenia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion - Barchart

Sep 30, 2024
pulisher
Sep 25, 2024

Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online

Sep 25, 2024
pulisher
Sep 18, 2024

Inari Medical director sells $1.83M in common stock - TipRanks

Sep 18, 2024
pulisher
Sep 18, 2024

Intuitive Machines Shares Soar on NASA Pact for Near-Space Grid - Bloomberg

Sep 18, 2024
pulisher
Sep 18, 2024

Intuitive Machines Stock Soars on New NASA Contract. This Is Big. - Barron's

Sep 18, 2024
pulisher
Sep 18, 2024

Intuitive Machines Stock Is Soaring Wednesday: What's Going On? - Benzinga

Sep 18, 2024
pulisher
Sep 18, 2024

Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga

Sep 18, 2024
pulisher
Sep 17, 2024

After-hours movers: Intuitive Machines, Casella Waste Systems, Galmed Pharma, Edgewise Therapeutics - Investing.com Australia

Sep 17, 2024
pulisher
Sep 16, 2024

Minerva Neurosciences (NASDAQ:NERV) Receives New Coverage from Analysts at StockNews.com - Defense World

Sep 16, 2024
pulisher
Sep 15, 2024

Rathbones Group PLC Increases Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) - MarketBeat

Sep 15, 2024
pulisher
Sep 13, 2024

INmune Bio stock dips on $13M securities offering - MSN

Sep 13, 2024
pulisher
Aug 23, 2024

Minerva Neurosciences (NASDAQ:NERV) versus AC Immune (NASDAQ:ACIU) Head-To-Head Survey - Defense World

Aug 23, 2024
pulisher
Aug 22, 2024

StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World

Aug 22, 2024
pulisher
Aug 15, 2024

Rubertis Francesco De Net Worth (2024) - GuruFocus.com

Aug 15, 2024
pulisher
Aug 14, 2024

Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com - Defense World

Aug 14, 2024
pulisher
Aug 09, 2024

Research Analysts Issue Forecasts for Minerva Neurosciences, Inc.’s Q3 2024 Earnings (NASDAQ:NERV) - Defense World

Aug 09, 2024
pulisher
Aug 09, 2024

Minerva Neurosciences (NASDAQ:NERV) Price Target Cut to $5.00 - Defense World

Aug 09, 2024
pulisher
Aug 08, 2024

HC Wainwright Weighs in on Minerva Neurosciences, Inc.’s Q4 2024 Earnings (NASDAQ:NERV) - Defense World

Aug 08, 2024
pulisher
Aug 07, 2024

Minerva Neurosciences: Q2 Earnings Snapshot - San Antonio Express-News

Aug 07, 2024
pulisher
Aug 06, 2024

Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates - GlobeNewswire

Aug 06, 2024
pulisher
Aug 06, 2024

Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com - Defense World

Aug 06, 2024
pulisher
Jul 29, 2024

Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com - Defense World

Jul 29, 2024
pulisher
Jul 21, 2024

Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com - Defense World

Jul 21, 2024
pulisher
Jul 13, 2024

Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200 Day Moving Average of $4.42 - Defense World

Jul 13, 2024
pulisher
Jul 13, 2024

StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World

Jul 13, 2024
pulisher
Jul 12, 2024

Cognitive Behavioral Therapy for Insomnia Market Insights, Industry Outlook, Growing Trends with Top Key Players – MINERVA NEUROSCIENCES INC, CURRAX PHARMACEUTICALS LLC, Pfizer Inc., Sanofi, zydus cadila – TIMC - TIMC

Jul 12, 2024
pulisher
Jul 05, 2024

Minerva Neurosciences (NASDAQ:NERV) Stock Price Passes Below 200-Day Moving Average of $4.54 - Defense World

Jul 05, 2024
pulisher
Jul 03, 2024

Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates - Zacks Investment Research

Jul 03, 2024
pulisher
Jul 03, 2024

Are Options Traders Betting on a Big Move in Minerva Neurosciences (NERV) Stock? - Yahoo Lifestyle UK

Jul 03, 2024
pulisher
Jul 01, 2024

Design, Sarepta, Wave rise amid overall neurological index decline - BioWorld Online

Jul 01, 2024
pulisher
Jun 30, 2024

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates - Quantisnow

Jun 30, 2024
pulisher
Jun 30, 2024

Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market - Quantisnow

Jun 30, 2024
pulisher
Jun 30, 2024

Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates - Quantisnow

Jun 30, 2024
pulisher
Jun 29, 2024

Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023 - Quantisnow

Jun 29, 2024
pulisher
Jun 29, 2024

Minerva Neurosciences to Present at JMP Securities Life Sciences Conference - Quantisnow

Jun 29, 2024
pulisher
Jun 29, 2024

Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million - Quantisnow

Jun 29, 2024
pulisher
Jun 29, 2024

Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates - Quantisnow

Jun 29, 2024
pulisher
Jun 29, 2024

Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021 - Quantisnow

Jun 29, 2024
pulisher
Jun 29, 2024

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8 - Quantisnow

Jun 29, 2024

Minerva Neurosciences Inc Stock (NERV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):